KNOPMAN, David S.; AMIEVA, Helene; PETERSEN, Ronald C.; CHETELAT, Gael; HOLTZMAN, David M.; HYMAN, Bradley T.; NIXON, Ralph A.; JONES, David T.

doi:10.1038/s41572-021-00269-y

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

KNOPMAN, David S.

AMIEVA, Helene

Bordeaux population health [BPH]

PETERSEN, Ronald C.

Langue

Article de revue

Ce document a été publié dans

Nature reviews Disease primers. 2021-05-13, vol. 7, n° 1, p. 33

Résumé en anglais

Alzheimer disease (AD) is biologically defined by the presence of beta-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants. AD is a common cause of cognitive impairment acquired in midlife and late-life but its clinical impact is modified by other neurodegenerative and cerebrovascular conditions. This Primer conceives of AD biology as the brain disorder that results from a complex interplay of loss of synaptic homeostasis and dysfunction in the highly interrelated endosomal/lysosomal clearance pathways in which the precursors, aggregated species and post-translationally modified products of Abeta and tau play important roles. Therapeutic endeavours are still struggling to find targets within this framework that substantially change the clinical course in persons with AD.< Réduire

Mots clés en anglais

Alzheimer's disease

Diagnostic markers

Translational research

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Alzheimer disease

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche